11，Bargman JM.Management of minimal lesion glomerulonephritis:evidence－based recommendations.Kidney Int,1999;55(suppl 70):s3
22，Bugess E.Conservative treatment to slow deterioration of renal function:evidence-based recommendations.Kidney Int,1999;55(suppl 70):s17
33，Burgess E.Management of focal segmental glomerulosclerosis:evidence-based recommendations.Kidney Int,1999;55(suppl 70):s26
44，Jindal kk.Management of idiopathic crescentic and diffuse proliferative glomerulonephritis:evidence-based recommendations.Kidney Int,1999;55(suppl 70):s33
55，Levin A.Mangement of membranoproliferative glomerulonephritis:evidence－based recommendations.Kidney Int,1999;55(suppl 70):s41
66，Muirhead N.Management of idiopathic membranous nephropathy:evidence-based recommendations.Kidney Int,1999;55(suppl 70):s47
77，Nolin L,Courteau M.Management of IgA nephropathy:evidence-based recommendations.Kidney Int,1999;55(suppl 70):s56
88，Maschio and Marcntoni.Angiotensin convertine enzyme inhibitors in nondiabetic renal disease.Curr Opin in Nephrol and Hyperten,1998;7:253
99，Manttari M,Tiula E,AlikoskiT,et al.Effects of hypertension and dyslipdemia on the decline in renal function.Hypertension,1995;26:670
1010，Rayher BL,Byrne MJ.A prospective clinical trial comparing the treatment of idiopathic membranoues nephropathy and nephrotic syndrome with simvastatin and diet,verses diet alone.Clin Nephrol,1996;46:219
